Radiopharm Theranostics has reported encouraging initial results from the Phase 1 HEAT trial of its novel HER2-targeted radiopharmaceutical, 177Lu-RAD202, highlighting tumor uptake and a clean safety profile at the lowest dose with dose escalation approved.
- 177Lu-RAD202 demonstrated meaningful tumor uptake in heavily pre-treated HER2+ patients
- No dose-limiting toxicities observed at initial 30 mCi dose cohort
- Data Safety and Monitoring Committee approved escalation to 130 mCi dose
- Trial targets advanced solid tumors including breast and urothelial cancers
- Supports continued clinical development of a first-in-class radiopharmaceutical
Early Human Data Validates 177Lu-RAD202 Targeting in HER2+ Tumors
Radiopharm Theranostics (ASX:RAD) has unveiled initial Phase 1 data for its pioneering radiopharmaceutical, 177Lu-RAD202, showing encouraging tumor targeting and a favourable safety profile in patients with advanced HER2-positive solid tumors. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, stem from the lowest dose cohort of the ongoing HEAT trial, where three heavily pre-treated patients received 30 mCi dosing.
Importantly, the trial reported meaningful uptake of the radiolabeled antibody particularly in breast cancer lesions, with no dose-limiting toxicities or treatment discontinuations due to adverse events. Most side effects were mild to moderate (Grade 1–2), suggesting the therapy’s tolerability even in a difficult-to-treat population.
Dose Escalation Approved as Safety and Dosimetry Meet Expectations
The Data Safety and Monitoring Committee (DSMC) recently greenlit escalation to the next dose level of 130 mCi, reflecting confidence in the safety and radiation dosimetry profiles observed. Organ-level radiation absorption remained within clinically acceptable limits, supporting further dose increases to explore therapeutic efficacy. This decision aligns with Radiopharm’s strategy to identify the optimal therapeutic window for 177Lu-RAD202, which leverages a Lutetium-177 labelled single-domain antibody designed for deep tumour penetration and rapid clearance.
The HEAT trial’s Phase 0/1 design rigorously assesses biodistribution, pharmacokinetics, and safety while escalating doses to establish a recommended Phase 2 dose. This measured approach is crucial given the novelty of the radiopharmaceutical and the complexity of HER2-positive advanced cancers.
Positioning Within Radiopharm’s Broader Clinical Pipeline
Radiopharm’s announcement follows its recent milestone in the brain metastases imaging space, where the company completed enrolment in a Phase 2b trial of RAD 101, reporting 90% concordance with MRI as a diagnostic tool. This progress highlights Radiopharm’s diversified pipeline across radiotherapeutics and diagnostics targeting multiple solid tumor types, including lung, breast, prostate, and brain cancers. The company is advancing rapidly, with plans to initiate a pivotal Phase 3 trial for RAD 101 following the full data readout expected in June 2026.
177Lu-RAD202’s promising early results add to this momentum, underscoring Radiopharm’s commitment to harnessing radiopharmaceutical technology for oncology indications with high unmet need. The company’s dual listing on ASX and NASDAQ reflects growing investor interest in the radiotheranostics sector, where innovation is accelerating.
Next Steps and Clinical Watchpoints
While the initial findings are encouraging, the data represent only three patients at the lowest dose level. The upcoming dose escalation to 130 mCi will be critical to assess potential antitumor activity and further safety signals. Investors and clinicians alike will be watching closely for signs of efficacy as the trial progresses through higher dosing cohorts.
Given the competitive landscape of HER2-targeted therapies, Radiopharm’s approach with a radiopharmaceutical conjugate offers a distinctive mechanism that may complement or extend current treatment options. The company’s ability to navigate regulatory pathways and demonstrate clinical benefit will shape its future trajectory in this space.
Bottom Line?
Radiopharm’s early clinical data for 177Lu-RAD202 supports cautious optimism, but upcoming dose escalation results will be pivotal in defining its therapeutic promise.
Questions in the middle?
- Will higher dose cohorts reveal clear antitumor efficacy for 177Lu-RAD202?
- How will Radiopharm position 177Lu-RAD202 among existing HER2-targeted therapies?
- What regulatory hurdles might emerge as the trial advances to later phases?